AstraZeneca is expanding its partnership with Israel’s Immunai (see here previously), deepening its use of Immunai’s AMICA-OS artificial intelligence platform in oncology treatment development. Immunai will be eligible to receive up to $37.5 million during 2026 and 2027. https://www.calcalistech.com/ctechnews/article/bkhaclqcwe

Israel’s Immunai has used its immune system AI mapping platform to discover a novel therapeutic target for inflammatory bowel disease (IBD). Immunai has partnered with AstraZeneca who will develop the therapy, which if successful will earn Immunai up to $85 … Continue reading →